JaLCDOI 10.18926/AMO/56182
FullText URL 72_4_423.pdf
Author Sakakida, Kourin| Wei, Fan-Yan| Senokuchi, Takafumi| Shimoda, Seiya| Kakuma, Tatsuyuki| Araki, Eiichi| Tomizawa, Kazuhito| The Eperisone for Diabetes with Impaired tRNA (EDIT) Study Group|
Abstract Genetic variation in Cdk5 Regulatory Associated Protein 1-Like 1 (CDKAL1) is associated with the development of type 2 diabetes (T2D). Dysfunction of CDKAL1 impairs the translation of proinsulin, which leads to glucose intolerance. Eperisone, an antispasmodic agent, has been shown to ameliorate glucose intolerance in Cdkal1-deficient mice. We have launched a phase II clinical study to investigate the potential anti-diabetic effect of eperisone in T2D patients carrying risk or non-risk alleles of CDKAL1. The primary endpoint is the change of hemoglobin A1c (HbA1c) levels. We also examined whether the efficacy of eperisone in T2D patients is associated with CDKAL1 activity.
Keywords diabetes insulin secretion single nucleotide polymorphism glucose
Amo Type Clinical Study Protocol
Published Date 2018-08
Publication Title Acta Medica Okayama
Volume volume72
Issue issue4
Publisher Okayama University Medical School
Start Page 423
End Page 426
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30140092